221,286 Shares in Vanda Pharmaceuticals Inc. $VNDA Purchased by Monaco Asset Management SAM

Monaco Asset Management SAM purchased a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 221,286 shares of the biopharmaceutical company’s stock, valued at approximately $1,354,000. Vanda Pharmaceuticals comprises about 0.1% of Monaco Asset Management SAM’s investment portfolio, making the stock its 24th largest holding.

A number of other hedge funds have also recently bought and sold shares of the stock. Torren Management LLC acquired a new position in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $25,000. Russell Investments Group Ltd. boosted its holdings in shares of Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 5,328 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Vanda Pharmaceuticals by 3,010.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock valued at $92,000 after buying an additional 10,055 shares during the last quarter. Jain Global LLC bought a new position in shares of Vanda Pharmaceuticals in the fourth quarter valued at $94,000. Finally, Quarry LP bought a new position in shares of Vanda Pharmaceuticals in the third quarter valued at $53,000. 88.14% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. HC Wainwright lowered their target price on shares of Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, August 10th. B. Riley Financial reiterated a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen lowered shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Vanda Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $13.70.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $5.22 on Monday. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $315.60 million, a P/E ratio of -1.13 and a beta of 0.64. Vanda Pharmaceuticals Inc. has a 12 month low of $4.27 and a 12 month high of $9.94. The stock has a 50 day moving average of $5.67 and a 200-day moving average of $6.65.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. The business had revenue of $50.53 million during the quarter, compared to the consensus estimate of $61.92 million. As a group, equities research analysts predict that Vanda Pharmaceuticals Inc. will post -3 EPS for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.